专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20130172317A1 TRIAZINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION HAVING AN ANALGESIC ACTIVITY COMPRISING THE SAME 有权
标题翻译：具有包括其同源活性的TRIAZINE衍生物和药物组合物
公开(公告)号：US20130172317A1
公开(公告)日：2013-07-04
申请号：US13814346
申请日：2011-08-09
申请人： Hiroyuki Kai , Takayuki Kameyama , Tohru Horiguchi , Kentaro Asahi , Takeshi Endoh , Yasuhiko Fujii , Takuya Shintani , Ken'ichiroh Nakamura , Sae Jikihara , Tsuyoshi Hasegawa , Miho Oohara , Yukio Tada , Toshikatsu Maki , Akira Iida
发明人： Hiroyuki Kai , Takayuki Kameyama , Tohru Horiguchi , Kentaro Asahi , Takeshi Endoh , Yasuhiko Fujii , Takuya Shintani , Ken'ichiroh Nakamura , Sae Jikihara , Tsuyoshi Hasegawa , Miho Oohara , Yukio Tada , Toshikatsu Maki , Akira Iida
IPC分类号： C07D251/46 , C07D417/12 , C07D413/12 , C07D405/06 , C07D401/14 , C07D251/52 , C07D405/14 , C07D401/12 , C07D403/12 , C07D403/04 , C07D413/14
CPC分类号： C07D251/46 , C07D251/52 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/06 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14
摘要： The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect.A pharmaceutical composition having an analgesic effect or an improving effect of urination disorder comprising a compound of the formula (I): wherein Rh and Rj are taken together to form a bond; Ra and Rb and/or Rd and Re are taken together to form oxo or the like; Rc is hydrogen, substituted or unsubstituted alkyl or the like; Rf is —(CR4aR4b)n—R2; R4a and R4b are hydrogen, substituted or unsubstituted alkyl or the like; R2 is substituted or unsubstituted cycloalkyl or the like; n is an integer of 1 to 4; —Rg is —X—R3; —X— is —O—, —S— or the like; R3 is substituted or unsubstituted cycloalkyl or the like, or its pharmaceutically acceptable salt or a solvate thereof.
摘要翻译：本发明提供具有P2X3和/或P2X2 / 3受体拮抗作用的新化合物。一种具有止痛作用或排尿障碍改善作用的药物组合物，其包含式（I）化合物：其中Rh和Rj一起形成键; Ra和Rb和/或Rd和Re一起形成氧代等; Rc是氢，取代或未取代的烷基等; Rf是 - （CR4aR4b）n-R2; R4a和R4b是氢，取代或未取代的烷基等; R2是取代或未取代的环烷基等; n为1〜4的整数， -Rg为-X-R3; -X-是-O-，-S-等; R3是取代或未取代的环烷基等，或其药学上可接受的盐或溶剂合物。

2. 发明授权

US09718790B2 Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same 有权
公开(公告)号：US09718790B2
公开(公告)日：2017-08-01
申请号：US13814346
申请日：2011-08-09
申请人： Hiroyuki Kai , Tohru Horiguchi , Kentaro Asahi , Yasuhiko Fujii
发明人： Hiroyuki Kai , Tohru Horiguchi , Kentaro Asahi , Yasuhiko Fujii
IPC分类号： C07D251/46 , C07D401/12 , C07D401/14 , C07D403/12 , C07D413/12 , C07D417/12 , A61P25/02 , C07D401/06 , C07D403/06 , C07D405/06 , C07D405/12 , C07D409/06 , C07D413/06 , C07D413/14 , C07D417/06 , C07D417/14 , C07D251/52 , C07D403/04 , C07D405/14
CPC分类号： C07D251/46 , C07D251/52 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/06 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/06 , C07D417/12 , C07D417/14
摘要： The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect.A pharmaceutical composition having an analgesic effect or an improving effect of urination disorder comprising a compound of the formula (I): wherein Rh and Ri are taken together to form a bond; Ra and Rb and/or Rd and Re are taken together to form oxo or the like; Rc is hydrogen, substituted or unsubstituted alkyl or the like; Rf is —(CR4aR4b)n—R2; R4a and R4b are hydrogen, substituted or unsubstituted alkyl or the like; R2 is substituted or unsubstjtuted cycloalkyl or the like; n is an integer of 1 to 4; —Rg is —X—R3; —X— is —O—, —S— or the like; R3 is substituted or unsubstituted cycloalkyl or the like, or its pharmaceutically acceptable salt or a solvate thereof.

3. 发明申请

US20110183939A1 NOVEL PYROLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME 失效
标题翻译：新颖的吡咯烷酮衍生物和药物组合物
公开(公告)号：US20110183939A1
公开(公告)日：2011-07-28
申请号：US13121072
申请日：2009-09-24
申请人： Hiroyuki Kai , Yoshiyuki Taoda , Takeshi Endoh , Tohru Horiguchi , Kentaro Asahi , Hiroyuki Tobinaga
发明人： Hiroyuki Kai , Yoshiyuki Taoda , Takeshi Endoh , Tohru Horiguchi , Kentaro Asahi , Hiroyuki Tobinaga
IPC分类号： A61K31/695 , A61K31/4439 , C07D487/04 , A61K31/422 , A61K31/4162 , A61K31/444 , C07F7/02 , A61K31/4245 , C07D413/14 , A61K31/5377
CPC分类号： C07D487/04 , C07D207/38 , C07D401/04 , C07D401/10 , C07D403/04 , C07D405/14 , C07D409/10 , C07D409/14 , C07D413/10 , C07D413/14 , C07D417/04
摘要： The present invention provides a novel P2X3 and/or P2X2/3 receptor antagonist.A compound represented by the formula (I); wherein Z1 is optionally protected hydroxy, etc.; Z2 is —C(═O)—, etc.; Z3a and Z3b are taken together ═O or ═S; t is an integer of 0 to 4; R4a and R4b are each independently, hydrogen or substituted or unsubstituted lower alkyl, etc.; m and n are each independently an integer of 0 to 2; k is an integer of 0 or 1; Ring A is an aromatic carbocyclic ring or a heterocyclic ring, etc.; B is aromatic carbocyclic ring-diyl or heterocyclic ring-diyl, etc.; R1a and R1b are each independently halogen, hydroxy, substituted or unsubstituted lower alkyl, etc.; R2 is substituted or unsubstituted alkyl, etc.; R3 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group, etc.; or its pharmaceutically acceptable salt, or a solvate thereof is provided.
摘要翻译：本发明提供了一种新型的P2X3和/或P2X2 / 3受体拮抗剂。由式（I）表示的化合物; 其中Z1是任选保护的羟基等; Z2是-C（= O） - 等; Z3a和Z3b合在一起= = 0或= t为0〜4的整数; R4a和R4b各自独立地为氢或取代或未取代的低级烷基等; m和n各自独立地为0〜2的整数。 k是0或1的整数; 环A是芳族碳环或杂环等; B是芳族碳环环 - 二基或杂环环二基等; R1a和R1b各自独立地为卤素，羟基，取代或未取代的低级烷基等; R2是取代或未取代的烷基等; R3是取代或未取代的烷基，取代或未取代的芳基或取代或未取代的杂环基等; 或其药学上可接受的盐或其溶剂合物。

4. 发明申请

US20130225596A1 NOVEL HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (AS AMENDED) 有权
标题翻译：新型杂环衍生物和药物组合物（如修饰）
公开(公告)号：US20130225596A1
公开(公告)日：2013-08-29
申请号：US13816085
申请日：2011-08-09
申请人： Hiroyuki Kai , Takeshi Endoh , Sae Jikihara , Kentaro Asahi , Tohru Horiguchi
发明人： Hiroyuki Kai , Takeshi Endoh , Sae Jikihara , Kentaro Asahi , Tohru Horiguchi
IPC分类号： C07C233/75 , C07D239/84 , C07D213/74 , C07C217/84 , C07D211/72 , C07D405/06 , C07C217/80 , C07D413/12 , C07D409/12 , C07D409/06 , C07D277/28 , C07D401/14 , C07D237/04
CPC分类号： C07D239/545 , C07C217/80 , C07C217/84 , C07C217/92 , C07C233/25 , C07C233/75 , C07C2601/14 , C07D211/72 , C07D213/64 , C07D213/69 , C07D213/74 , C07D213/79 , C07D213/80 , C07D213/82 , C07D215/22 , C07D215/56 , C07D217/22 , C07D217/24 , C07D231/38 , C07D233/88 , C07D233/96 , C07D235/30 , C07D237/04 , C07D237/20 , C07D237/32 , C07D239/42 , C07D239/47 , C07D239/48 , C07D239/54 , C07D239/557 , C07D239/78 , C07D239/84 , C07D239/95 , C07D239/96 , C07D241/20 , C07D255/02 , C07D261/12 , C07D263/32 , C07D263/34 , C07D263/48 , C07D265/06 , C07D265/10 , C07D265/26 , C07D265/36 , C07D277/20 , C07D277/28 , C07D277/34 , C07D277/38 , C07D277/42 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D405/14 , C07D407/06 , C07D409/06 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14
摘要： The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect.A pharmaceutical composition having a P2X3 and/or P2X2/3 receptor antagonistic effect comprising a compound of the formula (I): wherein ring A is substituted or unsubstituted 5 to 7-membered cycloalkane, substituted or unsubstituted 5 to 7-membered cycloalkene or the like; C is a carbon atom; —X— is —N(R16)— or the like; R16 is hydrogen, substituted or unsubstituted alkyl or the like; R7 is substituted or unsubstituted 5- or 6-membered heteroaryl, substituted or unsubstituted 6 to 10 membered aryl; Q1 and Q2 are each independently a carbon atom or a nitrogen atom; -L- is —O—, —S— or the like; R6 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl or the like; R2 is hydrogen, hydroxy or the like, or its pharmaceutically acceptable salt or a solvate thereof.
摘要翻译：本发明提供具有P2X3和/或P2X2 / 3受体拮抗作用的新化合物。一种具有P2X3和/或P2X2 / 3受体拮抗作用的药物组合物，其包含式（I）化合物：其中环A是取代或未取代的5至7元环烷烃，取代或未取代的5至7元环烯烃或喜欢; C是碳原子; -X-是-N（R 16） - 等; R 16是氢，取代或未取代的烷基等; R 7是取代或未取代的5元或6元杂芳基，取代或未取代的6至10元芳基; Q1和Q2各自独立地为碳原子或氮原子; -L-是-O-，-S-等; R6是取代或未取代的环烷基，取代或未取代的环烯基等; R2是氢，羟基等，或其药学上可接受的盐或其溶剂合物。

5. 发明授权

US09212130B2 Heterocyclic derivative and pharmaceutical composition comprising the same 有权
标题翻译：杂环衍生物和包含其的药物组合物
公开(公告)号：US09212130B2
公开(公告)日：2015-12-15
申请号：US13816085
申请日：2011-08-09
申请人： Hiroyuki Kai , Takeshi Endoh , Sae Jikihara , Tohru Horiguchi
发明人： Hiroyuki Kai , Takeshi Endoh , Sae Jikihara , Tohru Horiguchi
IPC分类号： A61K31/505 , A61K31/497 , A61K31/44 , A61K31/135 , A61K31/425 , C07C233/75 , C07C217/84 , C07C217/80 , C07D401/14 , C07D239/84 , C07D211/72 , C07D237/04 , C07C217/92 , C07D213/74 , C07D213/80 , C07D213/82 , C07D215/22 , C07D217/24 , C07D231/38 , C07D233/96 , C07D235/30 , C07D237/32 , C07D239/42 , C07D239/47 , C07D239/54 , C07D239/95 , C07D239/96 , C07D241/20 , C07D255/02 , C07D261/12 , C07D263/32 , C07D263/34 , C07D263/48 , C07D265/10 , C07D265/26 , C07D265/36 , C07D277/20 , C07D277/34 , C07D277/38 , C07D401/12 , C07D405/12 , C07D405/14 , C07D417/12 , C07D417/14 , C07D277/28 , C07D405/06 , C07D409/06 , C07D409/12 , C07D413/12 , C07D407/06 , C07C233/25 , C07D215/56 , C07D217/22 , C07D233/88 , C07D237/20 , C07D239/48 , C07D239/545 , C07D239/557 , C07D239/78 , C07D265/06 , C07D277/42 , C07D213/69
CPC分类号： C07D239/545 , C07C217/80 , C07C217/84 , C07C217/92 , C07C233/25 , C07C233/75 , C07C2601/14 , C07D211/72 , C07D213/64 , C07D213/69 , C07D213/74 , C07D213/79 , C07D213/80 , C07D213/82 , C07D215/22 , C07D215/56 , C07D217/22 , C07D217/24 , C07D231/38 , C07D233/88 , C07D233/96 , C07D235/30 , C07D237/04 , C07D237/20 , C07D237/32 , C07D239/42 , C07D239/47 , C07D239/48 , C07D239/54 , C07D239/557 , C07D239/78 , C07D239/84 , C07D239/95 , C07D239/96 , C07D241/20 , C07D255/02 , C07D261/12 , C07D263/32 , C07D263/34 , C07D263/48 , C07D265/06 , C07D265/10 , C07D265/26 , C07D265/36 , C07D277/20 , C07D277/28 , C07D277/34 , C07D277/38 , C07D277/42 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D405/14 , C07D407/06 , C07D409/06 , C07D409/12 , C07D413/12 , C07D417/12 , C07D417/14
摘要： The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect.A pharmaceutical composition having a P2X3 and/or P2X2/3 receptor antagonistic effect comprising a compound of the formula (I): wherein ring A is substituted or unsubstituted 5 to 7-membered cycloalkane, substituted or unsubstituted 5 to 7-membered cycloalkene or the like; C is a carbon atom; —X— is —N(R16)— or the like; R16 is hydrogen, substituted or unsubstituted alkyl or the like; R7 is substituted or unsubstituted 5- or 6-membered heteroaryl, substituted or unsubstituted 6 to 10 membered aryl; Q1 and Q2 are each independently a carbon atom or a nitrogen atom; -L- is —O—, —S— or the like; R6 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl or the like; R2 is hydrogen, hydroxy or the like, or its pharmaceutically acceptable salt or a solvate thereof.
摘要翻译：本发明提供具有P2X3和/或P2X2 / 3受体拮抗作用的新化合物。一种具有P2X3和/或P2X2 / 3受体拮抗作用的药物组合物，其包含式（I）化合物：其中环A是取代或未取代的5至7元环烷烃，取代或未取代的5至7元环烯烃或喜欢; C是碳原子; -X-是-N（R 16） - 等; R 16是氢，取代或未取代的烷基等; R 7是取代或未取代的5元或6元杂芳基，取代或未取代的6至10元芳基; Q1和Q2各自独立地为碳原子或氮原子; -L-是-O-，-S-等; R6是取代或未取代的环烷基，取代或未取代的环烯基等; R2是氢，羟基等，或其药学上可接受的盐或其溶剂合物。

6. 发明授权

US5665468A Magneto-optical recording medium 失效
标题翻译：磁光记录介质
公开(公告)号：US5665468A
公开(公告)日：1997-09-09
申请号：US269680
申请日：1994-07-01
申请人： Masahiko Sekiya , Tohru Horiguchi , Kiyoshi Chiba
发明人： Masahiko Sekiya , Tohru Horiguchi , Kiyoshi Chiba
IPC分类号： G11B11/105 , G11B5/66 , B32B5/16
CPC分类号： G11B11/10593 , G11B11/10506 , G11B11/10521 , G11B11/10591 , Y10S428/90 , Y10T428/12868 , Y10T428/12889 , Y10T428/12896 , Y10T428/1291 , Y10T428/12931 , Y10T428/26 , Y10T428/265
摘要： A magneto-optical recording medium in which direct overwriting can be done by only modifying the power level and/or the pulse width of applied optical pulses, and without changing the direction of the bias magnetic field. The recording layer comprises first and second magnetic recording layers. The first magnetic layer is a rare-earth transition metal-amorphous alloy and has a perpendicular easy magnetization axis, a thickness of 10 to 200 nm, and a compensation temperature above room temperature. The second magnetic layer comprises an alloy of a first component of Co and/or Fe and a second component of a rare earth metal and/or a noble metal or an alloy of Co and at least one metal selected from Ti, Cr, Mn, Cu, Zn, Ga and Ge. The second magnetic layer is a material having an in-plane easy magnetization axis such that it has a magnetization axis parallel to the second magnetic layer if formed independently on a dielectric layer, the second magnetic layer having a thickness of not more than 3 nm.
摘要翻译：一种磁光记录介质，其中可以通过仅修改施加的光脉冲的功率电平和/或脉冲宽度，并且不改变偏置磁场的方向来进行直接重写。记录层包括第一和第二磁记录层。第一磁性层是稀土过渡金属非晶合金，具有垂直的易磁化轴，厚度为10-200nm，补偿温度高于室温。第二磁性层包括Co和/或Fe的第一组分和稀土金属和/或贵金属或Co的合金的第二组分和选自Ti，Cr，Mn， Cu，Zn，Ga和Ge。第二磁性层是具有面内易磁化轴的材料，使得如果独立地形成在电介质层上，则具有平行于第二磁性层的磁化轴，第二磁性层的厚度不大于3nm。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式